Eevia Health Adjusts Financial Calendar Amid Audit Delays

Eevia Health Plc, a company renowned for its sustainable production of bioactive compounds, has announced changes to its financial calendar. The company has delayed the publication of its Q2-2025 interim report from August 21 to August 29, 2025. This decision comes in light of delays in receiving an unqualified auditor's report and finalizing the financial statements for 2024. The company aims to avoid any misrepresentations that might arise if the financial statements and balance sheet as of December 31, 2024, undergo further changes due to the audit.

In addition to the delay in the interim report, Eevia Health plans to release its statutory financial statements and the auditor’s report on August 29, 2025, provided the auditor’s report is received by that date. This move is crucial for maintaining transparency and accuracy in financial reporting, which is essential for investor confidence.

The company's Annual General Meeting (AGM) is now scheduled for September 15, 2025. While the notice for the AGM has been published on August 21, the related documents will be made available in the coming days.

Eevia Health, founded in 2017, focuses on addressing significant health problems using bioactive compounds extracted from plant materials sourced primarily from the Finnish and Swedish forests. The company prides itself on its environmentally friendly practices, offering a short value chain and competitive pricing. Listed on the Spotlight Stock Market in Sweden, Eevia Health has a reputation for transparency and sustainability.

Given the current situation, potential investors might feel uncertain. However, Eevia Health's commitment to transparency and sustainable practices remains a strong point. The delay in financial reporting, while concerning, is a strategic move to ensure accuracy. Investors should consider holding their positions until more clarity is provided post-publication of the financial statements and auditor's report.